Sanofi : Présentation (en anglais)

Q1 2021 Results

Play to Win

April 28, 2021

Forward looking statements

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

2

Agenda

Introduction

Business update

Financial results

Paul Hudson	Chief Executive Officer
Bill Sibold	Specialty Care
Thomas Triomphe	Vaccines
Olivier Charmeil	General Medicines
Julie Van Ongevalle	Consumer Healthcare
Jean-Baptiste de Chatillon	Chief Financial Officer

Q&A session

3

Q1 financial performance fueled by growth drivers

Sales and EPS growth

Company Sales	+2.4%
Q1 2021				€8,591m
				€8,973m
Q1 2020

Business EPS	+15%
Q1 2021(1)	€1.61
Q1 2020	€1.53

Dupixent® sales strong

	€1,047m
€776m	+46%
Q1 2020	Q1 2021

Vaccines delivered

Resilient PPH growth

€909m	€915m +5.3%
	PPH
	+15%
Q1 2020	Q1 2021

All growth at CER unless footnoted;. Dupixent® in collaboration with Regeneron	4
(1) Q1 2021 Business EPS excluding payment from Daiichi Sankyo was €1.53 with a growth of +9.8% at CER

Expanding affordable access to those most in need

Recognized for making medicines more easily available in low- and middle-income countries(1)

Sanofi rankings in

#5

#7

Creation of

SANOFI GLOBAL HEALTH

1st global initiative to provide

30	to	40
essential	of the world's
medicines		poorest countries

2018 2021

(1) The 2021 Access to Medicine Index ranks 20 pharmaceutical companies including Sanofi: GlaxoSmithKline, Novartis, Johnson & Johnson, Pfizer, Takeda, AstraZeneca,	5
Merck KGaA, Roche, Novo Nordisk, Eisai, Boehringer Ingelheim, Bayer, Astellas, Gilead, Merck & Co, Daiichi Sankyo, AbbVie, Eli Lilly, and Bristol Myers Squibb